Current therapies for chronic obstructive pulmonary disease (COPD) alleviate symptoms, but do not deal with disease progression. Respiratory mucus is primarily made up of mucins, of which mucin 5AC ...
Iron metabolism imbalance and ferroptosis are central to PF pathogenesis, offering new therapeutic targets. Ferroptosis links oxidative stress, iron overload, and fibrotic remodeling, affecting key ...
Chronic obstructive pulmonary disease (COPD) is among the most leading causes of death around the world and there are insufficient treatment options that prevent exacerbations or alter the progression ...
Affinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results